My watch list  

Ibandronic acid

Ibandronic acid
Systematic (IUPAC) name
propyl]phosphonic acid
CAS number 114084-78-5
ATC code M05BA06
PubChem 60852
DrugBank APRD00231
Chemical data
Formula C9H23NO7P2 
Mol. mass 319.229 g/mol
Pharmacokinetic data
Bioavailability 0.6%
Protein binding 90.9 to 99.5%
Metabolism Nil
Half life 10 to 60 hours
Excretion Renal
Therapeutic considerations
Licence data


Pregnancy cat.


Legal status

Prescription only

Routes Oral, intravenous

Ibandronic acid (INN) or ibandronate sodium (USAN), marketed under the trade names Boniva®, Bondronat® and Bonviva®, is a potent bisphosphonate drug used in the prevention and treatment of osteoporosis. It may also be used to treat hypercalcemia (elevated blood calcium levels).


Ibandronate is indicated for the treatment and prevention of osteoporosis in postmenopausal women. Ibandronate was approved by the U.S. Food and Drug Administration (FDA) in May 2003 as a 2.5 mg daily treatment for postmenopausal osteoporosis. The basis for this approval was a 3-year, randomized, double-blind, placebo-controlled trial of 2,946 women with postmenopausal osteoporosis. Participants in this study received placebo or oral ibandronate either daily (2.5 mg) or intermittently (20 mg every other day for 12 doses at the start of each 3-month interval). All study participants also received 500 mg of oral calcium and 400 international units of vitamin D daily. At the conclusion of the study, both doses significantly reduced the risk of new vertebral fractures by 50% to 52% when compared to placebo.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ibandronic_acid". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE